---
figid: PMC11020118__hep-79-1220-g002
pmcid: PMC11020118
image_filename: hep-79-1220-g002.jpg
figure_link: /pmc/articles/PMC11020118/figure/F1/
number: FIGURE 1
figure_title: ''
caption: 'Pathway summarizing screening and monitoring recommendations. Flow diagram
  summarizing hepatobiliary disease screening and monitoring recommendations, as outlined
  within the manuscript. Blue color indicates screening, and yellow color indicates
  monitoring. 1Should be performed at the time of clinical stability. 2CFHBI includes
  elevation in liver enzymes above age-appropriate values for >3â€“6 months, abnormal
  liver/spleen exam, and/or abnormal US findings. 3Advanced CF Liver Disease (aCFLD)
  refers to having one (or more) of the following: nodular liver, advanced fibrosis
  (F4), multilobular cirrhosis with or without portal hypertension, or noncirrhotic
  portal hypertension. Abbreviations: aCFLD, advanced CF liver disease; ALT, alanine
  aminotransferase; AST, aspartate aminotransferase; CF, cystic fibrosis; CFHBI, CF
  hepatobiliary involvement; GGT, gamma-glutamyl transferase; SWE, shear-wave elastography;
  TE, transient elastography; US, ultrasound.'
article_title: Cystic fibrosis screening, evaluation, and management of hepatobiliary
  disease consensus recommendations.
citation: Zachary M. Sellers, et al. Hepatology. 2024 May;79(5):1220-1238.
year: '2024'

doi: 10.1097/HEP.0000000000000646
journal_title: Hepatology (Baltimore, Md.)
journal_nlm_ta: Hepatology
publisher_name: Lippincott Williams & Wilkins

keywords:
---
